CN110196335A - 与肾功能相关的生物标记及其使用方法 - Google Patents

与肾功能相关的生物标记及其使用方法 Download PDF

Info

Publication number
CN110196335A
CN110196335A CN201910484069.9A CN201910484069A CN110196335A CN 110196335 A CN110196335 A CN 110196335A CN 201910484069 A CN201910484069 A CN 201910484069A CN 110196335 A CN110196335 A CN 110196335A
Authority
CN
China
Prior art keywords
renal function
acetyl
subject
purposes
ckd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910484069.9A
Other languages
English (en)
Chinese (zh)
Inventor
R·皮里崇
J·E·寇博
M·V·布朗
A·肯尼迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabolon Inc
Original Assignee
Metabolon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolon Inc filed Critical Metabolon Inc
Publication of CN110196335A publication Critical patent/CN110196335A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/64—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving ketones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201910484069.9A 2013-05-14 2014-05-13 与肾功能相关的生物标记及其使用方法 Pending CN110196335A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361822965P 2013-05-14 2013-05-14
US61/822,965 2013-05-14
CN201480027332.7A CN105209909B (zh) 2013-05-14 2014-05-13 与肾功能相关的生物标记及其使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480027332.7A Division CN105209909B (zh) 2013-05-14 2014-05-13 与肾功能相关的生物标记及其使用方法

Publications (1)

Publication Number Publication Date
CN110196335A true CN110196335A (zh) 2019-09-03

Family

ID=51898805

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910484069.9A Pending CN110196335A (zh) 2013-05-14 2014-05-13 与肾功能相关的生物标记及其使用方法
CN201480027332.7A Active CN105209909B (zh) 2013-05-14 2014-05-13 与肾功能相关的生物标记及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480027332.7A Active CN105209909B (zh) 2013-05-14 2014-05-13 与肾功能相关的生物标记及其使用方法

Country Status (10)

Country Link
US (2) US10539575B2 (https=)
EP (3) EP3410115A1 (https=)
JP (1) JP6595984B2 (https=)
CN (2) CN110196335A (https=)
AU (1) AU2014265669B2 (https=)
BR (1) BR112015028253A2 (https=)
CA (2) CA3184836A1 (https=)
ES (2) ES2702123T3 (https=)
MX (2) MX365061B (https=)
WO (1) WO2014186311A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021232211A1 (zh) * 2020-05-19 2021-11-25 深圳市中医院 诊断肾病的标志物以及诊断方法

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3184836A1 (en) * 2013-05-14 2014-11-20 Metabolon, Inc. Biomarkers related to kidney function and methods using the same
CN111879948A (zh) 2013-10-17 2020-11-03 综合医院公司 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
CA2973116C (en) * 2015-01-09 2023-08-15 Global Genomics Group, LLC Blood based biomarkers for diagnosing atherosclerotic coronary artery disease
WO2016115496A1 (en) * 2015-01-15 2016-07-21 Joslin Diabetes Center Metabolite biomarkers predictive of renal disease in diabetic patients
US11266730B2 (en) 2015-09-29 2022-03-08 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for BCG therapy
US20170234874A1 (en) * 2015-10-07 2017-08-17 Clearbridge Biophotonics Pte Ltd. Integrated visual morphology and cell protein expression using resonance-light scattering
US12057228B1 (en) 2015-12-30 2024-08-06 Cerner Innovation, Inc. Predicting newly incident chronic kidney disease
AU2017301949B2 (en) * 2016-07-28 2021-09-23 Metabolon, Inc. Compounds, reagents, and uses thereof
WO2018097793A1 (en) * 2016-11-25 2018-05-31 Baeckhed Fredrik Metabolic disorders
ES3004083T3 (en) * 2016-12-19 2025-03-11 Metabolon Inc Mass spectrometry assay method for detection and quantitation of kidney function metabolites
CN108956790A (zh) * 2017-05-18 2018-12-07 中国人民解放军第二军医大学第二附属医院 一组氨基酸标志物在急性肾损伤诊断试剂盒中的应用
CN107132266A (zh) * 2017-06-21 2017-09-05 佛山科学技术学院 一种基于随机森林的水质分类方法及系统
US11026625B2 (en) 2017-08-08 2021-06-08 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
CN107326093B (zh) * 2017-09-04 2020-01-21 东南大学 基于Taqman探针的慢性肾脏病相关基因检测荧光定量PCR一步法试剂盒及其应用
JP7163375B2 (ja) * 2017-09-28 2022-10-31 メタボルン インコーポレーティッド 化合物、試薬、およびそれらの使用
WO2019144081A1 (en) * 2018-01-19 2019-07-25 Mars, Incorporated Biomarkers and classification algorithms for chronic kidney disease in cats
EP3821254A1 (en) * 2018-07-14 2021-05-19 Mars Incorporated Biomarkers and test models for chronic kidney disease
WO2020171158A1 (ja) * 2019-02-20 2020-08-27 株式会社パートナーファーム 固相反応チップ及びこれを用いた測定方法
CN112305089B (zh) * 2019-07-26 2022-04-29 长沙都正生物科技股份有限公司 一种慢性肾病诊断生物标记物及其应用
MX2022001087A (es) * 2019-07-26 2022-04-07 Fundacio Inst Dinvestigacio Biomedica De Bellvitge Idibell Ergotioneina, s-metil-ergotioneina, y usos de las mismas.
CN111487338B (zh) * 2020-04-16 2022-06-10 中南大学湘雅二医院 一种与肾功能相关的无创生物标记物及其应用
AU2020480974A1 (en) 2020-12-07 2023-07-13 Kimberly-Clark Worldwide, Inc. Methods and consumer products for detecting a metabolite
CN114910587B (zh) * 2022-05-12 2024-03-19 军科正源(上海)生物医药科技有限公司 一种尿液检测用高效液相-串联质谱分析方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712084A (en) * 1995-09-08 1998-01-27 Research Corporation Technologies, Inc. Donor kidney viability test for improved preservation
CN102187219A (zh) * 2008-08-29 2011-09-14 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CN102272328A (zh) * 2008-11-22 2011-12-07 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
US20120034240A1 (en) * 2010-08-06 2012-02-09 Pronota N.V. Perlecan as a biomarker for renal dysfunction
CN102458418A (zh) * 2009-06-08 2012-05-16 夸克医药公司 治疗慢性肾病的方法
WO2013048344A1 (en) * 2011-09-29 2013-04-04 National University Of Singapore Urinary metabolomic markers for renal insufficiency
US20130115649A1 (en) * 2010-05-19 2013-05-09 Jeffrey Richard Shuster Methods and Reagents for Metabolomics and Histology in a Biological Sample and a Kit for the Same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02196787A (ja) 1989-01-25 1990-08-03 Otsuka Pharmaceut Co Ltd シュードウリジン誘導体
JPH0661278B2 (ja) 1990-09-18 1994-08-17 旭化成工業株式会社 ミオイノシトールの高感度定量法および定量用組成物
CN101377492B (zh) 2007-08-29 2014-04-23 北京九强生物技术股份有限公司 胱抑素c测定试剂盒
US9421330B2 (en) 2008-11-03 2016-08-23 Bayer Healthcare Llc Mitigation of contrast-induced nephropathy
US20100273207A1 (en) 2009-04-24 2010-10-28 Raymond Langley Methods for Diagnosis of Sepsis and Risk of Death
JP5197846B2 (ja) 2009-04-30 2013-05-15 紀陽 田仲 腎疾患重篤度を判定する方法又は装置若しくはその作動方法
US8709816B2 (en) 2009-09-04 2014-04-29 Tohoku University Human renal disease marker substance
WO2011075744A1 (en) 2009-12-20 2011-06-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5916058B2 (ja) 2011-08-26 2016-05-11 国立大学法人東北大学 細胞ストレス状態のバイオマーカー
JP2014530350A (ja) 2011-09-14 2014-11-17 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 腎臓毒性を評価するための手段及び方法
CA3184836A1 (en) * 2013-05-14 2014-11-20 Metabolon, Inc. Biomarkers related to kidney function and methods using the same
AU2017301949B2 (en) * 2016-07-28 2021-09-23 Metabolon, Inc. Compounds, reagents, and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712084A (en) * 1995-09-08 1998-01-27 Research Corporation Technologies, Inc. Donor kidney viability test for improved preservation
CN102187219A (zh) * 2008-08-29 2011-09-14 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CN102272328A (zh) * 2008-11-22 2011-12-07 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CN102458418A (zh) * 2009-06-08 2012-05-16 夸克医药公司 治疗慢性肾病的方法
US20130115649A1 (en) * 2010-05-19 2013-05-09 Jeffrey Richard Shuster Methods and Reagents for Metabolomics and Histology in a Biological Sample and a Kit for the Same
US20120034240A1 (en) * 2010-08-06 2012-02-09 Pronota N.V. Perlecan as a biomarker for renal dysfunction
WO2013048344A1 (en) * 2011-09-29 2013-04-04 National University Of Singapore Urinary metabolomic markers for renal insufficiency

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021232211A1 (zh) * 2020-05-19 2021-11-25 深圳市中医院 诊断肾病的标志物以及诊断方法
CN114026427A (zh) * 2020-05-19 2022-02-08 深圳市中医院 诊断肾病的标志物以及诊断方法
CN114026427B (zh) * 2020-05-19 2023-11-17 深圳市中医院 诊断肾病的标志物以及诊断方法

Also Published As

Publication number Publication date
US20200103417A1 (en) 2020-04-02
ES2702123T3 (es) 2019-02-27
US20160116486A1 (en) 2016-04-28
EP3546940B1 (en) 2021-02-17
EP2997366A4 (en) 2017-04-12
CA2911204A1 (en) 2014-11-20
EP2997366B1 (en) 2018-10-10
EP3546940A1 (en) 2019-10-02
MX365061B (es) 2019-05-22
JP6595984B2 (ja) 2019-10-23
CA2911204C (en) 2023-03-28
EP2997366A1 (en) 2016-03-23
MX391220B (es) 2025-03-21
MX2015015561A (es) 2016-02-05
CN105209909A (zh) 2015-12-30
CA3184836A1 (en) 2014-11-20
CN105209909B (zh) 2019-06-07
JP2016520192A (ja) 2016-07-11
BR112015028253A2 (pt) 2017-07-25
WO2014186311A1 (en) 2014-11-20
AU2014265669A1 (en) 2015-12-24
ES2871823T3 (es) 2021-11-02
MX2019005748A (es) 2019-08-12
HK1218331A1 (zh) 2017-02-10
EP3410115A1 (en) 2018-12-05
HK1222905A1 (en) 2017-07-14
US10539575B2 (en) 2020-01-21
AU2014265669B2 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
CN110196335A (zh) 与肾功能相关的生物标记及其使用方法
US10823744B2 (en) Methods and systems for metabolite and/or lipid-based detection of colorectal cancer and/or adenomatous polyps
JP2013525801A (ja) 自閉症の代謝バイオマーカー
JP2016530504A (ja) 自閉症スペクトラム障害のバイオマーカー
CN117074698B (zh) 用于急性心肌梗死早期诊断的标志物组合、试剂盒、系统和用途
Chen et al. Targeting amine-and phenol-containing metabolites in urine by dansylation isotope labeling and liquid chromatography mass spectrometry for evaluation of bladder cancer biomarkers
CN116519812A (zh) 生物标志物在制备妊娠糖尿病诊断试剂中的用途
KR20250079925A (ko) 경도 인지 장애의 평가 방법, 산출 방법, 평가 장치, 산출 장치, 평가 프로그램, 산출 프로그램, 기록 매체, 평가 시스템 및 단말 장치
JP5522365B2 (ja) 代謝物の異常度の取得方法、代謝異常の判定方法、及びそのプログラム、並びに、代謝物の異常度の取得装置、及び代謝異常の判定に基づく診断プログラム
CN114758719B (zh) 一种结直肠癌预测系统及其应用
US20170176477A1 (en) Means and methods to diagnose liver toxicity using putrescine as biomarker
JP2024134806A (ja) 唾液を用いた閉塞性睡眠時無呼吸症候群の診断補助方法
JP2014032046A (ja) 糖尿病性腎症鑑別用マーカー及びその用途
TWI858977B (zh) 生物標記物組、為個體提供老化標記物水平表示的方法、用於提供對個體的生物年齡預測的方法及套組
Nakorn et al. Untargeted analysis of the plasma metabolome in canine acute pancreatitis
CN117191963B (zh) 预测会否进展为aclf或者aclf患者会否死亡的生物标志物、系统及其应用
HK1218331B (zh) 与肾功能相关的生物标记及其使用方法
CN112305123B (zh) 小分子物质在动脉粥样硬化性脑梗死中的应用
HK1222905B (en) Biomarkers related to kidney function and methods using the same
CA2875331A1 (en) Methods for diagnosing chronic valvular disease
CN120064503A (zh) 用于抑郁症诊断的代谢性生物标记物组合
WO2015050783A1 (en) Biomarkers for kidney cancer and methods using the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190903

WD01 Invention patent application deemed withdrawn after publication